Organon to present new Phase 3 analysis of VTAMA in atopic dermatitis
OGN•Organon will present a Phase 3 analysis of VTAMA for moderate-to-severe atopic dermatitis on November 14, 2026, in Phoenix, highlighting consistent efficacy over time across patient subgroups.
1. Planned presentation
Organon will present the analysis at the American College of Allergy, Asthma & Immunology meeting. It evaluates differences in affected skin area and other baseline characteristics.
2. VTAMA indications
VTAMA cream is indicated for atopic dermatitis in patients aged 2 years and older, as well as plaque psoriasis in adults.
